Publications by authors named "Yongmei Yin"

Article Synopsis
  • A study evaluated the effectiveness and safety of Disitamab Vedotin (RC48) for treating advanced HER2-positive and HER2-low metastatic breast cancer (MBC) among Chinese patients.
  • *A total of 154 patients were analyzed, revealing a median progression-free survival of 5.06 months and an objective response rate of 36.36%, with HER2-positive patients faring better than those with low HER2 expression.
  • *The results indicate that RC48 is a promising treatment with a good safety profile, and combining it with other therapies could enhance its effectiveness for these patients.
View Article and Find Full Text PDF

Background: Patients with advanced solid tumors have a suboptimal prognosis. This study investigated the safety and feasibility of linperlisib, a selective phosphatidylinositol 3-kinase delta isoform (PI3Kδ) inhibitor, for treating patients with advanced solid tumors.

Methods: In this phase Ib, single-arm, open-label, multi-center clinical trial, patients with histologically confirmed advanced solid tumors from eight centers in China were enrolled to receive oral linperlisib (80 mg/day).

View Article and Find Full Text PDF

Human epidermal growth factor receptor 2 (HER2)-low breast cancer is a newly identified targetable subset of breast tumors, and its clinical characteristics and treatment strategies are controversial. The emergence of novel anti-HER2 antibody-drug conjugate (ADC) has brought promising approaches for HER2-low breast cancer treatment. Several clinical trials have validated the efficacy and safety of trastuzumab deruxtecan (T-Dxd) in HER2-low breast cancer at different treatment settings.

View Article and Find Full Text PDF
Article Synopsis
  • Helicobacter pylori (H. pylori) is increasingly resistant to antibiotics globally, complicating treatment efforts for infections.
  • A new whole genome sequencing (WGS) assay was developed to analyze 73 H. pylori strains from patients in Tianjin, China, linking specific genetic mutations to antibiotic resistance.
  • Four super-resistant strains were identified that formed biofilms, indicating that biofilm formation is another mechanism of resistance, suggesting that biofilm-related genes could be valuable for resistance screening.
View Article and Find Full Text PDF
Article Synopsis
  • - The MONARCH plus study found that adding abemaciclib to endocrine therapy significantly improved progression-free survival (PFS) and objective response rate (ORR) in postmenopausal women with HR+/HER2- advanced breast cancer.
  • - In the study, cohort A (no prior systemic therapy) showed a median PFS of 28.27 months for abemaciclib users compared to 14.73 months for those on placebo, while cohort B (progression on prior therapy) showed 11.41 months vs. 5.59 months, respectively.
  • - Although abemaciclib was associated with some adverse events, they were manageable, and it demonstrated a trend toward overall survival (OS
View Article and Find Full Text PDF

Background: Immune checkpoint blockade (ICB) has made remarkable achievements, but newly identified armored and cold tumors cannot respond to ICB therapy. The high prevalence of concomitant medications has huge impact on immunotherapeutic responses, but the clinical effects on the therapeutic outcome of armored and cold tumors are still unclear.

Methods: In this research, using large-scale transcriptomics datasets, the expression and potential biological functions of angiotensin II receptor 1 (AGTR1), the target of angiotensin receptor blocker (ARB), were investigated.

View Article and Find Full Text PDF

Background: Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Committee.

Methods: Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO BC experts, the CSCO BC guidelines determine the levels of recommendations for clinical application.

View Article and Find Full Text PDF

About 20% of breast cancer patients are positive for HER2. The efficacy of current treatments is limited by primary and secondary resistance to trastuzumab. tRNA-derived fragments (tRFs) have shown crucial regulatory roles in various cancers.

View Article and Find Full Text PDF

Background: Breast cancer (BC) is the world's largest tumor species in which hormone receptor-positive patients have relatively good prognosis. However, majority of patients will develop late resistance, one of the important factors is due to the loss of the original estrogen receptor (ER) expression.

Methods: We conducted this study in 115 patients with BC who experienced second biopsy at Jiangsu Province Hospital (JSPH) and divided patients into two subgroups ER + to - and ER + to + .

View Article and Find Full Text PDF

The use of trastuzumab emtansine (T-DM1) has revealed significant efficacy in HER2-positive metastatic breast cancer (MBC). However, optimal therapeutic strategies following T-DM1 failure remain a subject of debate in clinical practice. In this multicenter, retrospective, real-world study, we sought to examine the effectiveness and safety of tyrosine kinase inhibitors (TKIs) as a therapeutic strategy in HER2-positive MBC who developed T-DM1 resistance.

View Article and Find Full Text PDF

Purpose: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors.

Methods: This global, multi-center, first-in-human, phase I trial was conducted at 33 centers.

View Article and Find Full Text PDF

Nowadays, immunotherapy is one of the most promising anti-tumor therapeutic strategy. Specifically, immune-related targets can be used to predict the efficacy and side effects of immunotherapy and monitor the tumor immune response. In the past few decades, increasing numbers of novel immune biomarkers have been found to participate in certain links of the tumor immunity to contribute to the formation of immunosuppression and have entered clinical trials.

View Article and Find Full Text PDF
Article Synopsis
  • A study introduces a multifunctional nanozyme that effectively targets and eradicates Helicobacter pylori in acidic stomach environments, utilizing various enzymatic activities to generate reactive oxygen species.
  • The nanozyme is designed to enhance targeting and biocompatibility while minimizing effects in the intestines, demonstrating promise in treating infections without traditional drugs while also promoting healing of stomach tissues.
View Article and Find Full Text PDF

Background: Significant progress has been made in immunotherapy of breast cancer (BC) with the approval of multiple immune checkpoint inhibitors (ICIs), particularly in early and metastatic triple-negative breast cancer (TNBC) settings. Most guidelines have recommended immune therapy as the important approach in BC, yet several critical aspects still require further clarification, including proper patient selection, treatment duration, optimized chemotherapy partner, predictive biomarkers, and specific considerations for Chinese patients.

Methods: (I) Establishment of expert group: the expert group consists of 32 experts from departments such as medical oncology, breast surgery, and pathology; (II) literature search: mainly conducted in English databases (such as PubMed, Embase, and Cochrane Library) and Chinese databases (such as China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Database), with a search cutoff date of April 23, 2024; (III) assessment of evidence quality and recommendation strength: evidence quality and recommendation opinions are graded based on the evidence category and recommendation level of the Chinese Society of Clinical Oncology (CSCO) guidelines; (IV) consensus formulation: on the March 2, 2024, through online consensus meeting, the consensus content is thoroughly discussed, and opinions from all experts are solicited.

View Article and Find Full Text PDF

Background: For patients with hormone receptor-positive HER2-negeative metastatic breast cancer (HRHER2 MBC), switching to another cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) or targeted drugs with different mechanism are considerable treatment strategies post-CDK4/6i. However, no clinical data has been reported on which of the two strategies is more effective. In order to explore optimal treatment option post-CDK4/6i, we performed a retrospective comparative cohort study to evaluate the efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib.

View Article and Find Full Text PDF

Background: The ACE study previously demonstrated that tucidinostat (chidamide), a subtype-selective histone deacetylase (HDAC) inhibitor, plus exemestane significantly improved progression-free survival (PFS) in advanced hormone receptor-positive (HR) breast cancer patients with a manageable safety profile. The analysis of long-term safety and overall survival (OS) is presented here.

Methods: ACE is a randomized, double-blind, placebo-controlled, phase 3 trial comparing tucidinostat 30 mg/twice weekly plus exemestane 25 mg/day versus placebo plus exemestane 25 mg/day in postmenopausal patients with advanced, HR breast cancer.

View Article and Find Full Text PDF

Covalent organic frameworks (COFs) have demonstrated versatile application potential since their discovery. Although the structure of COFs is orderly arranged, the synthesis of controllable macrostructures still faces challenges. Herein, we report, to our knowledge, the first template-free self-assembled COF-18 Å hollow microtubule (MT-COF-18 Å) structure and its use for insulin delivery that exhibits high loading capacity, gastroresistance, and glucose-responsive properties.

View Article and Find Full Text PDF

tRNA-derived fragments (tRFs) play crucial roles in cancer progression. Among them, tRF-27 has been identified as a key factor in promoting trastuzumab resistance in HER2-positive breast cancer. However, the origin of tRF-27 remains uncertain.

View Article and Find Full Text PDF

Background: Immune checkpoint blockade (ICB) has revolutionized the treatment of various cancer types. Despite significant preclinical advancements in understanding mechanisms, identifying the molecular basis and predictive biomarkers for clinical ICB responses remains challenging. Recent evidence, both preclinical and clinical, underscores the pivotal role of the extracellular matrix (ECM) in modulating immune cell infiltration and behaviors.

View Article and Find Full Text PDF

Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have tended to prioritize HER2 and its associated signaling pathways, often overlooking broader but seemingly less relevant cellular processes, along with their associated genetic and epigenetic mechanisms. Here, transcriptome data is not only characterized but also examined epigenomic and 3D genome architecture information in both trastuzumab-sensitive and secondary-resistant breast cancer cells.

View Article and Find Full Text PDF

Pyroptosis has been reported to improve the antitumor effect by evoking a more intense immune response and a therapeutic effect. For phototherapy, several photosensitizers have been found to initiate pyroptosis. However, the effect of pyroptosis associated with apoptosis in enhancing the antitumor therapy needs sufficient characterization, especially under long-term treatment.

View Article and Find Full Text PDF
Article Synopsis
  • The study developed a diagnostic tool kit for detecting various inflammatory cytokines, which are crucial for understanding disease stages.
  • This kit utilizes DNA-encoded nanocatalysts to enable highly sensitive and quantitative detection of cytokines like CRP, PCT, and IL-6 at very low concentrations.
  • It shows potential for personalized treatment monitoring in breast cancer patients undergoing immunotherapy by providing a customized cytokine profile for each individual.
View Article and Find Full Text PDF

HER2-positive (HER2) metastatic breast cancer (mBC) is highly aggressive and a major threat to human health. Despite the significant improvement in patients' prognosis given the drug development efforts during the past several decades, many clinical questions still remain to be addressed such as efficacy when combining different therapeutic modalities, best treatment sequences, interindividual variability as well as resistance and potential coping strategies. To better answer these questions, we developed a mechanistic quantitative systems pharmacology model of the pathophysiology of HER2 mBC that was extensively calibrated and validated against multiscale data to quantitatively predict and characterize the signal transduction and preclinical tumor growth kinetics under different therapeutic interventions.

View Article and Find Full Text PDF

Importance: The bioequivalence of denosumab biosimilar has yet to be studied in a 53-week, multicenter, large-scale, and head-to-head trial. A clinically effective biosimilar may help increase access to denosumab in patients with solid tumor-related bone metastases.

Objectives: To establish the biosimilarity of MW032 to denosumab in patients with solid tumor-related bone metastases based on a large-scale head-to-head study.

View Article and Find Full Text PDF